Agena Bioscience has announced the launch of their FDA-EUA SARS-CoV-2 Panel for the qualitative detection of the novel coronavirus that causes COVID-19. Clinical laboratories can process more than 6000 samples each day running the iPLEX Pro SARS-CoV-2 Panel on a single MassARRAY^®  instrument, making it one of the highest throughput SARS-CoV-2 tests available.

Priced at under $10 per sample, the Panel makes large-scale testing more accessible. The single-reaction Panel targets five regions of the viral genome, providing the accuracy and sensitivity required in the evolving landscape of SARS-CoV-2 testing.

With the Panel's's release, Agena also aims to alleviate material shortages, enabling laboratories to accelerate testing without concerns about instrument or assay availability.

"The unique characteristics of the Agena detection technology provide significant supply chain advantages," explained Jason Halsey, Senior Vice President of Technology and Operations. "Agena proactively sourced and secured materials to provide uninterrupted product availability to our customers. Agena's's SARS-CoV-2 kits and MassARRAY systems are ready for immediate deployment, and we are equipped to supply millions of tests each month."

More information is available at www.agenabio.com, or you can make contact using the 'Request Information' button provided below.